Last updated on November 2017

This study is a Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease.


Brief description of study

This study is a Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease.

Detailed Study Description

Researchers are studying a drug called BAN2401 in people who have early Alzheimer's disease . People with Alzheimer's disease have a buildup of abnormal protein, known as amyloid, in their brains. BAN2401 may reduce the amount of this abnormal protein. The study drug will be given through injection into a vein. The purpose of this research is: to find out if the study drug has a benefit on a person's cognitive (mental) status using a series of specialized cognitive tests, to learn if the drug is safe and well-tolerated in people with early Alzheimer's disease and to discover how much of the drug is in the blood at different times after injection.

Clinical Study Identifier: TX9171

Contact Investigators or Research Sites near you

Start Over

Sharp Mesa Vista Hospital Clinical ...

Sharp Mesa Vista Hospital Clinical Research Center
San Diego, CA USA